Global Multiple Sclerosis Market

Multiple Sclerosis Market Size, Share, Growth Analysis, By Drug type(Immunomodulators, and Immunosuppressant), By Route of Administration(Injectables, Oral, and Others), By Diagnosis(Magnetic Resonance Imaging (MRI) Scans, Simple Electrical Stimulation Tests, and Lumbar Puncture), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35G2271 | Region: Global | Published Date: April, 2024
Pages: 214 | Tables: 89 | Figures: 71

Multiple Sclerosis Market Insights

Multiple Sclerosis Market size was valued at USD 26.04 Billion in 2023 and is poised to grow from USD 26.64 Billion in 2024 to USD 31.26 Billion by 2032, growing at a CAGR of 2.31% during the forecast period (2025-2032).

Multiple sclerosis (MS) is an immune-mediated illness that affects the central nervous system. Its defining traits include demyelination, inflammation, degenerative processes such as increased brain and spinal cord atrophy, and neuroaxonal loss. Monoclonal antibodies are being used to treat multiple sclerosis. Using these antibodies, various clinical trials are being done to develop novel multiple sclerosis drugs. Furthermore, most immunosuppressive drugs used to treat this disease are humanized monoclonal antibodies, which are in high demand worldwide. Multiple sclerosis diagnosis and therapy are becoming increasingly important worldwide as the disease's prevalence rises. As a result, the government actively promotes the multiple sclerosis treatment process.

Multiple sclerosis symptoms vary widely depending on the severity of the damage and the number of affected neurons. Fatigue, numbness, stiffness, urine incontinence, cognitive issues, emotional difficulties, and sorrow are among the symptoms that have been reported. The rise of the multiple sclerosis drug industry can be attributed to main market participants' increased emphasis on R&D to develop novel medications. Along with growing research effort, various research agreements between pharmaceutical companies and academic institutes have boosted the market for multiple sclerosis medicines even more.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Multiple Sclerosis Market size was valued at USD 25.45 billion in 2022 and is poised to grow from USD 26.04 billion in 2023 to USD 30.55 billion by 2031, growing at a CAGR of 2.31% in the forecast period (2024-2031).

Manufacturing locally to reduce operating costs is one of the primary business strategies used by manufacturers in the Multiple Sclerosis Treatment industry to benefit customers and expand the market segment. The Multiple Sclerosis Treatment industry has recently provided medicine with significant benefits. Major Multiple Sclerosis Treatment market participants such as Teva Pharmaceuticals, Bayer Healthcare, Biogen Idec, Pfizer Inc., and others are striving to boost market demand by supporting R&D efforts. 'Pfizer Inc. (US)', 'Novartis AG (Switzerland)', 'Bayer AG (Germany)', 'Eli Lilly and Company (US)', 'Merck & Co., Inc. (US)', 'Allergan (Ireland)', 'AstraZeneca (UK)', 'AbbVie Inc. (US)', 'Johnson & Johnson Private Limited (US)', 'Cipla Inc. (US)', 'Abbott (US)', 'Merck KGaA (Germany)', 'Actelion Pharmaceuticals Ltd (Switzerland)', 'Opexa Therapeutics, Inc. (US)', 'Bayer AG (Germany)'

The increasing frequency of multiple sclerosis is a major driver of the market's expansion. Multiple sclerosis is classified into four types: relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), and their high incidence rate would have an impact on market dynamics during the projection period.

Significant R&D Investments: Clinical research and R&D investments are drawing a lot of attention in the multiple sclerosis treatment sector. MS is a disease that numerous pharmaceutical companies are seeking to address. For example, Pipeline Therapeutics is using its PIPE-307, a selective M1 receptor antagonist, through clinical studies for multiple sclerosis. In addition to expanded research activity, several research agreements have been developed between pharmaceutical companies and research institutes, which has boosted the market for multiple sclerosis treatment. Pharmaceutical businesses of all sizes have been expanding their pipeline portfolio by conducting more research on innovative candidates. The debut of these pipeline prospects is likely to accelerate market expansion for multiple sclerosis treatments.

As the Asia Pacific region's healthcare sector grows rapidly, there will be an increased demand for healthcare experts. China and India are expected to dominate the multiple sclerosis treatment markets due to their large populations and high prevalence of the condition. China, India, and Malaysia will all make significant contributions to the Southeast Asian market's growth rate. Multiple sclerosis diagnoses are predicted to rise in Asian countries, particularly in the Asia Pacific area, as the demand for health care services grows. Asia-Pacific is predicted to expand the quickest over the projection period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Multiple Sclerosis Market

Report ID: SQMIG35G2271

$5,300
BUY NOW GET FREE SAMPLE